Sevelamer, chapter 2

Genzyme Corp.'s Renagel sevelamer hydrochloride dominates the market for phosphate binders based on its ability to control serum phosphate without causing metal accumulation or calcification. But it isn't perfect. GENZ believes that its next-generation product, Renvela sevelamer carbonate, which was approved by FDA last week, will retain the advantages of Renagel without its disadvantages.

The company plans to market both products, keeping patients who are well managed with Renagel on Renagel. New patients will start therapy with Renvela. Over time, GENZ plans to transition patients to the new product...